Hepatocellular adenoma surgery: Difference between revisions

	Hepatocellular adenoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hepatocellular adenoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hepatocellular adenoma surgery On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hepatocellular adenoma surgery All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hepatocellular adenoma surgery
CDC on Hepatocellular adenoma surgery
Hepatocellular adenoma surgery in the news
Blogs on Hepatocellular adenoma surgery
Directions to Hospitals Treating Hepatocellular adenoma
Risk calculators and risk factors for Hepatocellular adenoma surgery

VisualWikitext

Latest revision as of 02:20, 23 August 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2] Zahir Ali Shaikh, MD [3]

Overview

Surgical resection is the treatment of choice for hepatocellular adenoma larger than 5 cm in diameter, the ones that increase in size, lesions with intra-tumoral hemorrhage, and male patients (irrespective of the adenoma size). Liver transplantation may be considered for hepatocellular adenomas associated with glycogen storage disease type 1. Radiofrequency ablation (RFA) and transcatheter arterial embolization (TAE) may be considered for patients who are poor candidates for surgery.

Surgery

Surgery is the treatment of choice for hepatocellular adenoma.^[1]^[2]^[3]
Elective surgical resection of hepatocellular adenoma is considered for all adenoma lesions with the following characteristics:^[4]^[5]
- Lesions > 5 cm in diameter
- Lesions that increase in size
- Lesions with intratumoral hemorrhage
- Male patients (irrespective of adenoma size)
Liver transplantation may be considered for hepatocellular adenoma associated with glycogen storage disease type 1.^[6]
In adenoma patients who are poor candidates for surgery (centrally located lesions, multiple adenomas, and morbid obesity), radiofrequency ablation (RFA) and transcatheter arterial embolization (TAE) may be considered.
Radiofrequency ablation (RFA) is a minimally invasive technique that can be used for hepatocellular adenoma, hepatocellular carcinoma, and colorectal metastases as well.^[7]
Transcatheter arterial embolization (TAE) is used in adenoma patients with hemodynamic instability due to bleeding hyper-vascular arterial lesions.

Approach to the Management of Hepatocellular Adenoma Based on Clinical Features, Gender, Imaging Features, and Histology:

MRI features of hepatic adenoma

Asymptomatic

Symptomatic

Male & glycogen storage disease

Female

Hemodynamically stable

Hemodynamically unstable

Resection irrespective of size & subtype

Stop offending drugs

Radiofrequency ablation resection

Embolization resection

< 5 cm

> 5 cm

Steatotic (HNF1 a) Hepatic adenoma

Inflammatory hepatic adenoma

Beta catenin hepatic adenoma

Others

Consider resection

Followup, genetic counselling for MODY & hepatic adenomatosis

Close followup, treatment of obesity

Biopsy & resection if confirmed

Biopsy & treat based on subtype

References

↑ Paulette Bioulac-Sage, Herve Laumonier, Gabrielle Couchy, Brigitte Le Bail, Antonio Sa Cunha, Anne Rullier, Christophe Laurent, Jean-Frederic Blanc, Gaelle Cubel, Herve Trillaud, Jessica Zucman-Rossi, Charles Balabaud & Jean Saric (2009). "Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience". Hepatology (Baltimore, Md.). 50 (2): 481–489. doi:10.1002/hep.22995. PMID 19585623. Unknown parameter |month= ignored (help)
↑ Toso C, Majno P, Andres A, Rubbia-Brandt L, Berney T, Buhler L, Morel P, Mentha G (2005). "Management of hepatocellular adenoma: solitary-uncomplicated, multiple and ruptured tumors". World J Gastroenterol. 11 (36): 5691–5. PMID 16237767.Full text
↑ Ault GT, Wren SM, Ralls PW, Reynolds TB, Stain SC (1996). "Selective management of hepatic adenomas". Am Surg. 62 (10): 825–9. PMID 8813164.
↑ T. Terkivatan, J. H. de Wilt, R. A. de Man, R. R. van Rijn, H. W. Tilanus & J. N. IJzermans (2001). "Treatment of ruptured hepatocellular adenoma". The British journal of surgery. 88 (2): 207–209. doi:10.1046/j.1365-2168.2001.01648.x. PMID 11167868. Unknown parameter |month= ignored (help)
↑ J. Belghiti, D. Pateron, Y. Panis, V. Vilgrain, J. F. Flejou, J. P. Benhamou & F. Fekete (1993). "Resection of presumed benign liver tumours". The British journal of surgery. 80 (3): 380–383. PMID 8472159. Unknown parameter |month= ignored (help)
↑ Jan P. Lerut, Olga Ciccarelli, Christine Sempoux, Etienne Danse, Jacques deFlandre, Yves Horsmans, Etienne Sokal & Jean-Bernard Otte (2003). "Glycogenosis storage type I diseases and evolutive adenomatosis: an indication for liver transplantation". Transplant international : official journal of the European Society for Organ Transplantation. 16 (12): 879–884. doi:10.1007/s00147-003-0613-3. PMID 12904843. Unknown parameter |month= ignored (help)
↑ Maarten G. Thomeer, Mirelle Broker, Joanne Verheij, Michael Doukas, Turkan Terkivatan, Diederick Bijdevaate, Robert A. De Man, Adriaan Moelker & Jan N. IJzermans (2016). "Hepatocellular adenoma: when and how to treat? Update of current evidence". Therapeutic advances in gastroenterology. 9 (6): 898–912. doi:10.1177/1756283X16663882. PMID 27803743. Unknown parameter |month= ignored (help)

Template:WikiDoc Sources

[1] Paulette Bioulac-Sage, Herve Laumonier, Gabrielle Couchy, Brigitte Le Bail, Antonio Sa Cunha, Anne Rullier, Christophe Laurent, Jean-Frederic Blanc, Gaelle Cubel, Herve Trillaud, Jessica Zucman-Rossi, Charles Balabaud & Jean Saric (2009). "Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience". Hepatology (Baltimore, Md.). 50 (2): 481–489. doi:10.1002/hep.22995. PMID 19585623. Unknown parameter |month= ignored (help)

[cde-2] Toso C, Majno P, Andres A, Rubbia-Brandt L, Berney T, Buhler L, Morel P, Mentha G (2005). "Management of hepatocellular adenoma: solitary-uncomplicated, multiple and ruptured tumors". World J Gastroenterol. 11 (36): 5691–5. PMID 16237767.Full text

[pmid8813164-3] Ault GT, Wren SM, Ralls PW, Reynolds TB, Stain SC (1996). "Selective management of hepatic adenomas". Am Surg. 62 (10): 825–9. PMID 8813164.

[4] T. Terkivatan, J. H. de Wilt, R. A. de Man, R. R. van Rijn, H. W. Tilanus & J. N. IJzermans (2001). "Treatment of ruptured hepatocellular adenoma". The British journal of surgery. 88 (2): 207–209. doi:10.1046/j.1365-2168.2001.01648.x. PMID 11167868. Unknown parameter |month= ignored (help)

[5] J. Belghiti, D. Pateron, Y. Panis, V. Vilgrain, J. F. Flejou, J. P. Benhamou & F. Fekete (1993). "Resection of presumed benign liver tumours". The British journal of surgery. 80 (3): 380–383. PMID 8472159. Unknown parameter |month= ignored (help)

[6] Jan P. Lerut, Olga Ciccarelli, Christine Sempoux, Etienne Danse, Jacques deFlandre, Yves Horsmans, Etienne Sokal & Jean-Bernard Otte (2003). "Glycogenosis storage type I diseases and evolutive adenomatosis: an indication for liver transplantation". Transplant international : official journal of the European Society for Organ Transplantation. 16 (12): 879–884. doi:10.1007/s00147-003-0613-3. PMID 12904843. Unknown parameter |month= ignored (help)

[7] Maarten G. Thomeer, Mirelle Broker, Joanne Verheij, Michael Doukas, Turkan Terkivatan, Diederick Bijdevaate, Robert A. De Man, Adriaan Moelker & Jan N. IJzermans (2016). "Hepatocellular adenoma: when and how to treat? Update of current evidence". Therapeutic advances in gastroenterology. 9 (6): 898–912. doi:10.1177/1756283X16663882. PMID 27803743. Unknown parameter |month= ignored (help)

[1]

[2]

[3]

[4]

[5]

[6]

[7]

@@ Line 3: / Line 3: @@
 {{CMG}}; {{AOEIC}} {{CZ}} {{ZAS}}
 ==Overview==
-The [[Surgery|surgical]] [[resection]] is treatment of choice for [[Hepatocellular adenoma|hepatocellular adenomas]] that are >5cm in [[diameter]], that increase in size, [[Lesion|lesions]] with intra [[Tumor|tumoral]] [[hemorrhage]] and male patients (irrespective of the [[adenoma]] size). The [[liver transplantation]] may be considered for the [[Hepatocellular adenoma|hepatocellular adenomas]] associated with [[Glycogen storage disease type I|glycogen storage disease type 1]]. [[Radiofrequency ablation|Radiofrequency ablation (RFA)]] and transcatheter [[Artery|arterial]] [[embolization]] (TAE) may be considered for the [[adenoma]] patients who are poor candidates for [[surgery]].
+[[Surgical resection]] is the treatment of choice for hepatocellular adenoma larger than 5 cm in [[diameter]], the ones that increase in size, [[Lesion|lesions]] with intra-[[Tumor|tumoral]] [[hemorrhage]], and male [[Patient|patients]] (irrespective of the [[adenoma]] size). [[Liver transplantation]] may be considered for hepatocellular adenomas associated with [[Glycogen storage disease type I|glycogen storage disease type 1]]. [[Radiofrequency ablation|Radiofrequency ablation (RFA)]] and [[Transcatheter arterial chemoembolization|transcatheter arterial embolization]] ([[Transcatheter arterial chemoembolization|TAE]]) may be considered for [[Patient|patients]] who are poor candidates for [[surgery]].
-==Hepatocellular adenoma surgery==
+==Surgery==
-* [[Surgery]] is the treatment of choice for [[hepatocellular adenoma]], as it can achieved in a controlled and safe manner.<ref>{{Cite journal
+* [[Surgery]] is the treatment of choice for hepatocellular adenoma.<ref>{{Cite journal
   | author = [[Paulette Bioulac-Sage]], [[Herve Laumonier]], [[Gabrielle Couchy]], [[Brigitte Le Bail]], [[Antonio Sa Cunha]], [[Anne Rullier]], [[Christophe Laurent]], [[Jean-Frederic Blanc]], [[Gaelle Cubel]], [[Herve Trillaud]], [[Jessica Zucman-Rossi]], [[Charles Balabaud]] & [[Jean Saric]]
   | title = Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience
@@ Line 18: / Line 18: @@
   | pmid = 19585623
 }}</ref><ref name="cde">{{cite journal | author = Toso C, Majno P, Andres A, Rubbia-Brandt L, Berney T, Buhler L, Morel P, Mentha G | title = Management of hepatocellular adenoma: solitary-uncomplicated, multiple and ruptured tumors. | journal = World J Gastroenterol | volume = 11 | issue = 36 | pages = 5691-5 | year = 2005 | id = PMID 16237767}}''[http://www.wjgnet.com/1007-9327/11/5691.asp Full text]''</ref><ref name="pmid8813164">{{cite journal| author=Ault GT, Wren SM, Ralls PW, Reynolds TB, Stain SC| title=Selective management of hepatic adenomas. | journal=Am Surg | year= 1996 | volume= 62 | issue= 10 | pages= 825-9 | pmid=8813164 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8813164  }} </ref>
-* Elective [[Surgery|surgical]] [[resection]] of [[hepatocellular adenoma]] is considered for; all [[adenoma]] [[Lesion|lesions]] >5cm in [[diameter]], [[Lesion|lesions]] that increase in size, [[Lesion|lesions]] with [[Tumoral|intratumoral]] [[hemorrhage]] and male patients (irrespective of [[adenoma]] size).<ref>{{Cite journal
+* Elective [[Surgery|surgical]] [[resection]] of hepatocellular adenoma is considered for all [[adenoma]] [[Lesion|lesions]] with the following characteristics:<ref>{{Cite journal
   | author = [[T. Terkivatan]], [[J. H. de Wilt]], [[R. A. de Man]], [[R. R. van Rijn]], [[H. W. Tilanus]] & [[J. N. IJzermans]]
   | title = Treatment of ruptured hepatocellular adenoma
@@ Line 40: / Line 40: @@
   | pmid = 8472159
 }}</ref>
-* The [[liver transplantation]] may be considered for patients of [[hepatocellular adenoma]] associated with [[Glycogen storage disease type I|glycogen storage disease type 1]].<ref>{{Cite journal
+**[[Lesion|Lesions]] > 5 cm in [[diameter]]
+**[[Lesion|Lesions]] that increase in size
+**[[Lesion|Lesions]] with [[Tumoral|intratumoral]] [[hemorrhage]]
+**Male patients (irrespective of [[adenoma]] size)
+* [[Liver transplantation]] may be considered for hepatocellular adenoma associated with [[Glycogen storage disease type I|glycogen storage disease type 1]].<ref>{{Cite journal
   | author = [[Jan P. Lerut]], [[Olga Ciccarelli]], [[Christine Sempoux]], [[Etienne Danse]], [[Jacques deFlandre]], [[Yves Horsmans]], [[Etienne Sokal]] & [[Jean-Bernard Otte]]
   | title = Glycogenosis storage type I diseases and evolutive adenomatosis: an indication for liver transplantation
@@ Line 52: / Line 56: @@
   | pmid = 12904843
 }}</ref>
-* The [[adenoma]] patients who are poor candidates for [[surgery]] (centrally located [[Lesion|lesions]], multiple [[Adenoma|adenomas]], [[morbid obesity]]), [[Radiofrequency ablation|radiofrequency ablation (RFA)]] and transcatheter [[Artery|arterial]] [[embolization]] (TAE) may be considered.
+* In adenoma [[Patient|patients]] who are poor candidates for [[surgery]] (centrally located [[Lesion|lesions]], multiple [[Adenoma|adenomas]], and [[morbid obesity]]), [[Radiofrequency ablation|radiofrequency ablation (RFA)]] and transcatheter [[Artery|arterial]] [[embolization]] (TAE) may be considered.
-* [[Radiofrequency ablation|Radiofrequency ablation (RFA)]] is a minimally [[Invasive (medical)|invasive]] technique that can be used for [[Hepatocellular adenoma|hepatocellular adenomas]], [[hepatocellular carcinoma]] and [[colorectal]] [[Metastasis|metastases]] as well.<ref>{{Cite journal
+* [[Radiofrequency ablation|Radiofrequency ablation (RFA)]] is a [[Minimally invasive procedure|minimally invasive technique]] that can be used for hepatocellular adenoma, [[hepatocellular carcinoma]], and [[colorectal]] [[Metastasis|metastases]] as well.<ref>{{Cite journal
   | author = [[Maarten G. Thomeer]], [[Mirelle Broker]], [[Joanne Verheij]], [[Michael Doukas]], [[Turkan Terkivatan]], [[Diederick Bijdevaate]], [[Robert A. De Man]], [[Adriaan Moelker]] & [[Jan N. IJzermans]]
   | title = Hepatocellular adenoma: when and how to treat? Update of current evidence
@@ Line 65: / Line 69: @@
   | pmid = 27803743
 }}</ref>
-* Transcatheter [[Artery|arterial]] [[embolization]] (TAE) is used in [[adenoma]] patients with [[hemodynamic instability]] due to bleeding hypervascular [[Artery|arterial]] lesions.
+* [[Transcatheter arterial chemoembolization|Transcatheter arterial embolization]] ([[Transcatheter arterial chemoembolization|TAE]]) is used in [[adenoma]] [[Patient|patients]] with [[hemodynamic instability]] due to [[bleeding]] hyper-[[vascular]] [[Artery|arterial]] lesions.
+==== Approach to the Management of Hepatocellular Adenoma Based on Clinical Features, Gender, Imaging Features, and [[Histology]]: ====
-* The algorithm approach to management of [[hepatocellular adenoma]] based on clinical features, gender, imaging and [[histology]].
 {{familytree/start}}
 {{familytree | | | | | | | | | | | | | A01 | | | | | | | | | | | | | |A01=MRI features of hepatic adenoma }}
@@ Line 78: / Line 81: @@
 {{familytree | | | C01 | | | | | | C02 | | | C03 | | | | C04 | | | | |C01=Male & glycogen storage disease|C02=Female|C03=Hemodynamically stable|C04=Hemodynamically unstable }}
 {{familytree | | | |!| | | | | | | |!| | | | |!| | | | | |!| | | | | | }}
-{{familytree | | | D01 | | | | | | D02 | | | D03 | | | | D04 | | | | |D01=Resection irrespective of size & sybtype|D02=Stop offending drugs|D03=Radiofrequency ablation resection|D04=Embolization resection }}
+{{familytree | | | D01 | | | | | | D02 | | | D03 | | | | D04 | | | | |D01=Resection irrespective of size & subtype|D02=Stop offending drugs|D03=Radiofrequency ablation resection|D04=Embolization resection }}
 {{familytree | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | }}
 {{familytree | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | }}
 {{familytree | | | | | | | | |,|-|-|^|-|-|-|-|-|-|.| | | | | | | | | | }}
-{{familytree | | | | | | | | E01 | | | | | | | | E02 | | | | | | | | |E01=<5cm|E02=>5cm }}
+{{familytree | | | | | | | | E01 | | | | | | | | E02 | | | | | | | | |E01=< 5 cm|E02=> 5 cm }}
 {{familytree | | |,|-|-|-|v|-|^|-|v|-|-|-|.| | | |!| | | | | | | | | | | }}
 {{familytree | | |!| | | |!| | | |!| | | |!| | | |!| | | | | | | | | | | | | }}
-{{familytree | | F01 | | F02 | | F03 | | F04 | | F05 | | | | | | | | | | | | |F01=Steatotic (HNF1 a) Hepatic adenoma|F02=Inflammatory hepatic adenoma|F03=Beta catenin hepatic adenoma|F04=Otehrs|F05=Consider resection }}
+{{familytree | | F01 | | F02 | | F03 | | F04 | | F05 | | | | | | | | | | | | |F01=Steatotic (HNF1 a) Hepatic adenoma|F02=Inflammatory hepatic adenoma|F03=Beta catenin hepatic adenoma|F04=Others|F05=Consider resection }}
 {{familytree | | |!| | | |!| | | |!| | | |!| | | | | | | | | | | | | | | | | | }}
 {{familytree | | |!| | | |!| | | |!| | | |!| | | | | | | | | | | | | | | | | | }}
-{{familytree | | G01 | | G02 | | G03 | | G04 | | | | | | | | | | | | | | | | |G01=Followup, genetic counselling for MODY & hepatic adenomatosis|G02=Close followup, treatment of obesity & discontinue obesity|G03=Biopsy & resection if confirmed|G04=Biopsy & treat based on subtype }}
+{{familytree | | G01 | | G02 | | G03 | | G04 | | | | | | | | | | | | | | | | |G01=Followup, genetic counselling for MODY & hepatic adenomatosis|G02=Close followup, treatment of obesity|G03=Biopsy & resection if confirmed|G04=Biopsy & treat based on subtype }}
 {{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }}
 {{familytree/end}}